Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
CPRT has dropped 21% in a month to $26.62, yet short sellers are pulling back rather than pressing the trade, creating an unusual setup heading into November earnings.
The short position tells a story of capitulation rather than conviction. Short interest in Copart has fallen nearly 24% over the past month, from around 43 million shares in early September to just under 33 million now, bringing it to 3.4% of the free float. That is a meaningful retreat. The lending market offers no constraint on rebuilding a short: availability is effectively uncapped, with hundreds of millions of shares available to borrow and cost-to-borrow running at a negligible 0.43%. Shorts are leaving despite a falling stock price, not because it is expensive to stay in. Options traders are similarly relaxed. The put/call ratio has eased to 0.54, slightly below its 20-day average of 0.56 and about 1.5 standard deviations on the bullish side of that range. The 52-week high on the PCR was 0.67, so there is no rush for downside protection visible in derivatives either.
The Street is divided on what to make of this. Analyst consensus has shifted bullish after the September earnings drop, with JPMorgan upgrading to Overweight and raising its target to $40 in the days following the print. BNP Paribas has since lifted its own target to $43 while reiterating Outperform. But HSBC moved the other way, downgrading to Hold around the same time. Barclays remains the clearest bear, sitting at Underweight with a $25 target that is almost exactly where the stock trades today. The mean target of $39 implies roughly 47% upside from current levels, though that gap is partly a reflection of how fast the stock has fallen rather than an uplift in analyst confidence. Valuation has compressed sharply: the price-to-book multiple is down more than 17% over the past month, and the P/E has contracted by more than 15%. At 15.5 times trailing earnings, the stock is no longer obviously expensive, but the EV/EBITDA of 9.9 times still carries a premium to the broader industrials universe. The ORTEX factor score for analyst recommendation divergence sits at just 1 out of 100, flagging that the spread of views is unusually wide.
One concrete counterweight to the bearish price action is Copart's own capital allocation. According to EDGAR XBRL data compiled by ORTEX, the company recorded its largest-ever Q2 buyback spend in the April 2026 quarter at $1.41 billion, the highest quarterly figure since records began in 2009. That buyback at prices above today's levels does not reverse the earnings headwinds that triggered the post-results selloff, but it signals that management was treating the stock as cheap at significantly higher prices. The ORTEX alt data layer also flags that retail attention, measured by Wikipedia page views against the company's own 90-day history, was running at a z-score of 2.5 around mid-September, the week the stock broke sharply lower after results. Elevated attention during a selloff is a coincident signal, not a leading one, but it suggests the move drew a wide audience.
Institutional flows offer a modest constructive tilt. BlackRock added 4.4 million shares in its most recent filing to hold 7.3% of the company. Capital Research added around 900,000 shares. Founder Willis Johnson still holds nearly 5.9% with no reported change. On the insider side, the picture is less clear. CEO Jeffrey Liaw sold around 27,700 shares at $30.49 in late July under a pre-arranged 10b5-1 plan, a scheduled disposal rather than a discretionary judgment call. Director Daniel Englander sold 80,000 shares at $27.55 in mid-July outside of a plan, generating $2.2 million in proceeds. Net insider activity over the past 90 days was negative at roughly minus $3 million, though the 10b5-1 framing on the CEO trades substantially reduces the signal.
The next earnings date is November 19. The most recent print, September 10, produced a 6.5% one-day fall and a 7.4% five-day loss, amplifying a decline that had already begun. The question for the next six weeks is whether the combination of short-seller retreat, buyback credibility, and valuation compression at 15x earnings is enough to arrest the slide, or whether the bear case on weakening unit volumes and deteriorating auction pricing continues to drive the story.
See the live data behind this article on ORTEX.
Open CPRT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
